Date: 2014-10-13
Type of information: R&D agreement
Compound: preclinical studies of drug candidates of drug candidates from UCART (for Universal Chimeric Antigen Receptor – T cells) portfolio
Company: Cellectis (France) Oncodesign (France)
Therapeutic area: Cancer - Oncology
Type agreement: R&D
Action mechanism: The candidates from UCART (for Universal Chimeric Antigen Receptor – T cells) portfolio are advanced therapy medicinal products based on engineered allogeneic T cells using the CAR (Chimeric Antigen Receptor) technology combined with genome engineering. Engineered allogeneic T-lymphocytes bearing a CAR directed at a tumor antigen stand out as a genuine therapeutic innovation in the treatment of various forms of leukemias, lymphomas and solid tumors. UCARTs are special in that they are “off-the-shelf” allogeneic products. UCARTs’ production could be industrialized and thereby standardized, with consistent pharmaceutical release criteria. Each future patient may thus be dosed by receiving a single injection of a standard “off-the-shelf” product with consistent quality. The first clinical trial in humans is scheduled for 2015.
Disease:
Details: * On October 13 2014, Oncodesign, a biotechnology company serving the pharmaceutical industry in the discovery of new therapeutic molecules to fight cancer and other serious illnesses with no known efficient treatment, announced the signature of a major new research agreement with Cellectis to continue the collaboration first launched by the companies in 2013.Cellectis has selected Oncodesign to carry out certain preclinical studies of drug candidates from Cellectis’ UCART portfolio of engineered allogeneic T cells based on its CAR (Chimeric Antigen Receptor) technology together with genome engineering.
Oncodesign has been working for more than 15 years on the preclinical evaluation of immunotherapies used in the treatment of cancer and possesses perfectly suited technologies, such as predictive cancer models simulating the human immune system, medical imaging equipment and a secure AAALAC-accredited environment for performing tests involving genetically modified cells. This experience, plus the pre-existing relationship between the two companies, heavily influenced Cellectis’ decision.
Financial terms:
Latest news:
